The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Conferences ramp up, and ASH abstracts near.
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
The company reckons it’s got what it takes to hit the right member of the FGFR family.
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.